Status: Recruiting
Recombinant Human Thyroid Stimulating Hormone for Radioiodine 131I Treatment
Subjects: patients with postoperative local recurrent or metastatic differentiated thyroid cancer . Experimental group: Recombinant human thyroid stimulating hormone injection: 0.9mg/1.0mL/piece; intramuscular injection; once a day for two consecutive days. Control group: Thyroid hormone withdraw for 4-6 weeks. The two groups were treated with radioiodine 131I after plasma thyroid stimulating hormone elevated (\>30mU/L). The efficacy and adverse reactions were observed.
Participants needed: 30
Trial details
Age: 18-75Biological sex: AllType: InterventionalSponsor: Nanjing First Hospital, Nanjing Medical UniversityUpdated: May 8, 2024Locations: 1
Eligibility criteria
Age: 18~75 years old (including 18 and 75 years old); [+5]
Patients with severe and uncontrolled diseases, including: 1) Uncontrolled hyper... [+8]